Researchers Develop Novel Drug Delivery System
2/02/2012
Long duration, controllable drug delivery is of wide interest to medical researchers and clinicians, particularly those seeking to improve treatment for patients with chronic pain or to prevent cancer recurrence after surgery...
Research Highlights New Treatments, Compares Existing Therapies For Prostate Cancer
2/02/2012
Research on promising new therapies and data on the relative benefits of established treatments for prostate cancer have been released, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, Calif...
In Patients With Drug-Resistant Prostate Cancer, New Drug Extends Survival
2/02/2012
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression of prostate cancer...
Breast Cancer Surgery Often Repeated To Take Out More Tissue
2/01/2012
22.9% of breast cancer patients who undergo partial mastectomies need further operations to remove more tissue, researchers reported in JAMA (Journal of the American Medical Association)...
Erivedge - Treatment For Most Common Form Of Skin Cancer
2/01/2012
Basal cell carcinoma is a form of skin cancer caused by regular sun exposure, or other ultraviolet radiation, which starts in the top layer of the skin (epidermis), is usually painless and grows slowly. The U.S. Food and Drug Administration just approved a new drug named Erivedge (vismodegib) for the treatment of adult patients with basal cell carcinoma, the most common type of skin cancer...
Erivedge - Treatment For Most Common Form Of Skin Cancer
2/01/2012
Basal cell carcinoma is a form of skin cancer caused by regular sun exposure, or other ultraviolet radiation, which starts in the top layer of the skin (epidermis), is usually painless and grows slowly. The U.S. Food and Drug Administration just approved a new drug named Erivedge (vismodegib) for the treatment of adult patients with basal cell carcinoma, the most common type of skin cancer...
Improved Detection Of Colorectal Cancer By Flexible Sigmoidoscopy
2/01/2012
Repeated screening by flexible sigmoidoscopy (FSG) increased the detection of colorectal cancer or advanced adenoma in women by one-fourth and in men by one-third, according to a study published Jan. 31 in the Journal of the National Cancer Institute...
Preclinical Study Identifies New Target For Cancer Therapy
2/01/2012
Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors. Called tryptophan 2,3-dioxygenase or TDO, the enzyme works by depriving immune cells of tryptophan, an amino acid essential to their activity...
Improved Detection Of Colorectal Cancer By Flexible Sigmoidoscopy
2/01/2012
Repeated screening by flexible sigmoidoscopy (FSG) increased the detection of colorectal cancer or advanced adenoma in women by one-fourth and in men by one-third, according to a study published Jan. 31 in the Journal of the National Cancer Institute...
FDA Approves Drug For Common Skin Cancer
2/01/2012
On Monday, the US Food and Drug Administration approved a new type of drug to treat adult patients with advanced basal-cell carcinoma, the most common type of skin cancer. The drug's generic name is vismodegib and was developed by the US part of Roche Holding AG. It will be sold in the US by Roche's South San Francisco-based Genentech under the brand name Erivedge...